Hypertension is one of the major risk factors for cardiovascular morbidity and mortality. It has been shown that lowering blood pressure (BP) reduces cardiovascular morbidity and mortality. 1, 2 However, to what level BP should be lowered, and what the optimal BP in hypertensive patients should be remained a matter of debate. One view held by MacCaron et al 3 claimed that BP should be lowered to the lowest tolerable level to achieve the maximal benefit. Whereas the opposite view held by Cruickshank et al 4 claimed that too vigorous reduction in BP may be associated with increased cardiovascular risk-the so called 'J-curve' concept. The fear of the 'J-curve' led many physicians, all over the world, to be careful in prescribing antihypertensive medications and as a result as many as 70% of hypertensive patients are not well controlled according to the recent guidelines. 5 The Hypertension Optimal Treatment (HOT) study was designed to solve the longlasting dilemma of whether an aggressive approach of treatment by lowering diastolic BP much below 90 mm Hg is really beneficial.
The investigators of the HOT trial suggested that intensive lowering of BP in patients with hypertension, was associated with a low rate of cardiovascular events. 6 Moreover, they have claimed that lowering the diastolic BP down to 82.6 mm Hg is optimal. However this conclusion is not justified on the basis of the reported results.
Looking at the main outcome results, major cardiovascular events, all strokes, cardiovascular mortality and total mortality showed no benefit associated with diastolic BP reduction targeted in any of three groups (reduction aimed at levels below 90, 85, and 80 mm Hg respectively) in comparison with the other two. Indeed, the less than expected differences in the achieved mean BP in the three target groups could hamper the identification of a significant difference in cardiovascular event rates or allcause mortality among the three groups.
Nevertheless, in the diabetic hypertensive patients, for the same BP differences, event rates
Correspondence: Dr Ehud Grossman, Internal Medicine D, The Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel between the three groups did exhibit a clear and significant benefit in favour of lowering diastolic BP to below 80 mm Hg. An important point to ponder pertains to the findings related to non-diabetic hypertensive patients. Looking at the incidence of cardiovascular events and total mortality in these individuals, constituting 92% of the total HOT sample (Table 1) , there appears to be a clear disadvantage to the policy attempting the lowering of diastolic BP to below 80 mm Hg. In the latter group, increased risks of cardiovascular and all-cause mortality were observed. The large increase in all-cause mortality outweighs the small reduction in myocardial infarction incidence. This raises the possibility that, for non-diabetic hypertensive patients, the 'J curve' may in fact hold.
The analysis of events in relation to achieved BP gave some indication that the maximum benefits of treatment can be expected when the achieved systolic BP pressure is between 130 to 140 mm Hg and diastolic BP is between 80 and 85 mm Hg. However, the attempt to define 'the lowest point of risk' (at the mean achieved diastolic BP of 82.6 mm Hg) as the 'ideal target' is somehow biased because, in fact, the curve for myocardial infarction is flat, and for major cardiovacsular events, the risk differs little between 80 and 90 mm Hg. Given that the additional benefit of lowering BP below 140/90 mm Hg is marginal, one should consider the economic burden and the exposure to known and unknown side effects associated with aggressive therapy. Therefore a policy targeted to lower diastolic BP to below 90 mm Hg in non-diabetic hypertensive patients may unnecessarily expose many hypertensive patients to increased frequency of side effects and considerable expense.
The results of the HOT study clearly demonstrated that acetylsalicylic acid reduced major cardiovascular events in patients with hypertension with the greatest benefit seen in all myocardial infarction. The low dose of 75 mg acetylsalicylic acid had no effect on the incidence of stroke or fatal bleeds, but this does not imply that a higher dose of 325 mg would not reduce the rate of stroke.
In conclusion, the results of the HOT study show 
